agonists – Talk Bio

Takeda and Alkermes Detail Strong Clinical Results for Orexin Drugs in Narcolepsy – Head-to-Head Race Accelerates

1 week ago talkbio0Tagged agonists, alixorexton, Alkermes, Cataplexy, Clinical Trials, Daytime Somnolence, Excessive (qualifier value), Maintenance, MWT, Narcolepsy, orexins, oveporexton, Phase 3, Takeda, Wakefulness Test

Takeda; Alkermes; orexin agonists; narcolepsy; oveporexton; alixorexton; clinical trials; Phase 3; excessive daytime sleepiness; cataplexy; maintenance of wakefulness test (MWT)

Terns to Stop Funding Metabolic Disease Trials Beyond 2025; Seeks Partners for Assets

1 month ago talkbio0Tagged agonists, Clinical Trials, Glucagon-Like Peptide 1, Metabolic Diseases, Myeloid Leukemia, Chronic, Oncology Focus, Partnering, Pipeline Strategy, TERN-601, TERN-701, Terns

Terns Pharmaceuticals; metabolic disease; clinical trials; pipeline strategy; partnering; oncology focus; TERN-601; TERN-701; GLP-1 agonists; CML

Veru Survey Highlights Muscle Loss Concerns Among GLP-1 Users as Lean Mass-Preserving Drug Advances

2 months ago talkbio0Tagged agonists, Diet, High-Protein, Elderly (population group), enobosarm, GLP-1 receptor, Lean Mass, muscle loss, Obesity, Surveys, Veru

Veru; GLP-1 receptor agonists; muscle loss; enobosarm; lean mass; obesity; survey; older adults; high-protein diet

GLP-1s May Lower Cancer Risk; Gyre Stock Drops After Hep B Data, Share Offering

4 months ago talkbio0Tagged agonists, Cancer Risk, Clinical Data, GLP-1 receptor, Gyre stock, Hepatitis B, Mortality Vital Statistics, Obesity-Related Cancers

GLP-1 receptor agonists; cancer risk; obesity-related cancers; Gyre stock; hepatitis B; clinical data; mortality

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

8 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity

9 months ago talkbio0Tagged advancements, agonists, Chronic disease, Diabetes Mellitus, Non-Insulin-Dependent, Future, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide

GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements

UK Health Secretary Warns Against Misuse of GLP-1 Weight Loss Drugs for Aesthetic Purposes

10 months ago talkbio0Tagged agonists, Cautionary Warning, Esthetics (discipline), Glucagon-Like Peptide 1, health secretary, MHRA, MISUSE, UK, Weight Loss, Weight-Loss Agents

GLP-1 agonists, weight loss drugs, misuse, aesthetic weight loss, UK health secretary, MHRA warnings

Enhancing GI Tolerability of GLP-1 Receptor Agonists: A Path to Improved Therapeutic Outcomes

11 months ago talkbio0Tagged Administration occupational activities, agonists, Diabetes, gastrointestinal tolerability, GLP-1 receptor, Obesity, therapeutic strategies

GLP-1 receptor agonists, gastrointestinal tolerability, therapeutic strategies, diabetes management, obesity treatment

Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery

12 months ago talkbio0Tagged agonists, Biotechnology, Drug Discovery, G-Protein-Coupled Receptors, Hypoparathyroidism, IPO, Preclinical, PTH1R gene, Septerna

Septerna, IPO, GPCR, preclinical data, drug discovery, biotechnology, PTH1R agonists, hypoparathyroidism

Novo Nordisk’s GLP-1 Agonist Demonstrates Significant BMI Reduction in Children Aged 6-12 in Phase 3 Trial

1 year ago talkbio0Tagged agonists, Body mass index procedure, Glucagon-Like Peptide 1, liraglutide, Nordisk, Obesity, Pediatric brand name, Phase 3 trial, semaglutide

GLP-1 agonists, obesity, weight loss, liraglutide, semaglutide, pediatric obesity, BMI reduction, Novo Nordisk, Phase 3 trial.